NASDAQ: PBMPsyence Biomedical Ltd Stock
$0.19-0.04 (-17.39%)
Updated Sep 6, 2024
PBM Price
$0.19
Fair Value Price
N/A
Market Cap
$2.56M
52 Week Low
$0.18
52 Week High
$14.55
P/E
-0.02x
P/B
-0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$51.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.1
Operating Cash Flow
-$3M
Beta
-0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PBM Overview
Newcourt Acquisition Corp. is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets digital financial services and fintech companies with exposure to emerging markets. Newcourt Acquisition founded in 2021 and is headquartered in Oakland, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PBM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PBM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PBM due diligence checks available for Premium users.
Be the first to know about important PBM news, forecast changes, insider trades & much more!
PBM News
Valuation
PBM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-46.85x
Market
24.57x
PBM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.23x
Industry
6.22x
PBM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PBM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.1M
Liabilities
$12.1M
Debt to equity
-1.1
PBM's short-term liabilities ($12.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBM's short-term assets ($1.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PBM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PBM vs Biotech Stocks
Psyence Biomedical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.